Spyre officer sells 28,399 shares after option exercise
A Spyre Therapeutics officer exercised options and sold 28,399 common shares under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. (SYRE) officer Heidy King-Jones reported exercising stock options for 28,399 shares of common stock at an exercise price of $14.50 per share on September 1–2, 2026, and selling 28,399 shares of common stock in multiple transactions at prices up to $90.00 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026, with several sales reported at weighted-average prices reflecting trade ranges between $85.71 and $88.69 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 28,399 shares ($2.07M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
King-Jones Heidy
Role
See Remarks
Sold
28,399 shs ($2.48M)
Approx. gross sale proceeds
$2.48M
Approx. exercise cost
$412K
Approx. pre-tax spread
$2.07M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F6 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 400 | $14.50 | $6K |
| Sale | Common Stock F1, F2 | 400 | $90.00 | $36K |
| Exercise | Stock Option (Right to Buy) F1, F6 | 27,999 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 27,999 | $14.50 | $406K |
| Sale | Common Stock F1, F3, F2 | 4,845 | $86.40 | $419K |
| Sale | Common Stock F1, F4, F2 | 16,548 | $87.20 | $1.44M |
| Sale | Common Stock F1, F5, F2 | 6,206 | $88.17 | $547K |
| Sale | Common Stock F1, F2 | 400 | $89.38 | $36K |
Holdings After Transaction:
Stock Option (Right to Buy) — 511,411 contracts (Direct);
Common Stock — 2,845 shares (Direct)
Footnotes (6)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
- F2. Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Option shares exercised: 28,399 shares
Exercise price: $14.50 per share
Common shares sold: 28,399 shares
+5 more
8 metrics
Option shares exercised
28,399 shares
Common stock underlying options exercised on September 1–2, 2026
Exercise price
$14.50 per share
Exercise price for Spyre Therapeutics stock options converted into common stock
Common shares sold
28,399 shares
Total common stock sold in reported transactions on September 1–2, 2026
Sale price range (weighted-average blocks)
$85.71–$88.69 per share
Price ranges for blocks of sales on September 1, 2026, reported as weighted averages
Highest reported sale price
$90.00 per share
Price for a sale of 400 shares of common stock on September 2, 2026
Rule 10b5-1 plan adoption date
April 16, 2026
Adoption date of the trading plan governing the reported transactions
Option grant size
539,810 shares
Total shares covered by the option described in footnote F6
Reverse stock split ratio
1-for-25
Reverse stock split on September 8, 2023, used to adjust the option share count
Key Terms
Rule 10b5-1 trading plan, weighted average price, reverse stock split, employee stock purchase plan, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reverse stock split financial
"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
employee stock purchase plan financial
"shares of common stock acquired by the Reporting Person ... pursuant to the Issuer's employee stock purchase plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vested and became exercisable financial
"one quarter of which vested and became exercisable on September 1, 2024"
FAQ
What transactions did Spyre Therapeutics (SYRE) officer Heidy King-Jones report on this Form 4?
Heidy King-Jones reported exercising stock options for 28,399 shares of Spyre Therapeutics common stock at $14.50 per share on September 1–2, 2026, and then selling 28,399 shares of common stock in multiple transactions on those dates.
Were the Spyre Therapeutics (SYRE) trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026, and the Form 4 also affirms the Rule 10b5-1 checkbox, indicating the trades followed this pre-arranged plan.
What stock options did the SYRE officer exercise in these transactions?
Heidy King-Jones exercised options to acquire 28,399 shares of Spyre Therapeutics common stock at an exercise price of $14.50 per share. A footnote explains the option covers 539,810 shares in total, adjusted for a prior 1-for-25 reverse stock split.
What does the Form 4 say about the size and vesting of the Spyre Therapeutics option grant?
A footnote states the option represents the right to purchase 539,810 shares of Spyre Therapeutics common stock, adjusted for a 1-for-25 reverse stock split. One quarter vested on September 1, 2024, with the remaining three quarters vesting in monthly installments over three years.
How were some SYRE sale prices reported for Heidy King-Jones’ transactions?
Several sale lines report a weighted average price. Footnotes explain that on September 1, 2026, shares were sold in multiple trades within ranges of $85.71–$86.70, $86.71–$87.70, and $87.73–$88.69 per share, with full trade details available upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
